WO2001076585A2 - Use of thiamphenicol for the treatment of chlamydia pneumoniae infections - Google Patents

Use of thiamphenicol for the treatment of chlamydia pneumoniae infections Download PDF

Info

Publication number
WO2001076585A2
WO2001076585A2 PCT/EP2001/003709 EP0103709W WO0176585A2 WO 2001076585 A2 WO2001076585 A2 WO 2001076585A2 EP 0103709 W EP0103709 W EP 0103709W WO 0176585 A2 WO0176585 A2 WO 0176585A2
Authority
WO
WIPO (PCT)
Prior art keywords
thiamphemcol
chlamydia
pneumomae
treatment
infections
Prior art date
Application number
PCT/EP2001/003709
Other languages
English (en)
French (fr)
Other versions
WO2001076585A3 (en
Inventor
Giovanni Battista Colombo
Domenico Ungheri
Luciano Licciardello
Maria Rita Gismondo
Lorenzo Drago
Original Assignee
Zambon Group S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Group S.P.A. filed Critical Zambon Group S.P.A.
Priority to US09/926,738 priority Critical patent/US6833389B2/en
Priority to DE60111811T priority patent/DE60111811T2/de
Priority to JP2001574103A priority patent/JP4796258B2/ja
Priority to DK01940275T priority patent/DK1212049T3/da
Priority to EP01940275A priority patent/EP1212049B1/en
Priority to AT01940275T priority patent/ATE299020T1/de
Publication of WO2001076585A2 publication Critical patent/WO2001076585A2/en
Publication of WO2001076585A3 publication Critical patent/WO2001076585A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to the use of thiamphemcol and de ⁇ vatives thereof for the preparation of pharmaceutical compositions useful in the treatment of Chlamydia pneumomae infections
  • Chlamydia pneumomae is an intracellular bacte ⁇ um recently considered responsible of respiratory infections both of the upper tract and the lower tract This bacte ⁇ um is one of the most widespread human pathogens and p ⁇ mary infections in children from 5 to 14 years have been supported by documentary evidence In children the infection is generally mild and asymptomatic, but can be more se ⁇ ous in adult and elderly Chlamydia pneumomae is responsible for about 10% of cases of atypical pneumonia and of 5% of cases of bronchitis It has also been associated with respiratory airways diseases and with new onset asthma and asthmatic bronchitis in the adults Sinusitis caused by Chlamydia pneumomae also associated with infections of the lower respiratory tract has been descnbed and, moreover, Chlamydia pneumomae has been isolated from middle ear fluids of patients with otitis media For a survey of the pathologies associated to Chlamydia pneumomae infections see F
  • azithromycm and, in particular, cla ⁇ thromycin resulted active in vitro against Chlamydia pneumomae and others agents involved in these infections and therefore they are potential therapeutical agents in the treatment of Chlamydia pneumomae infections
  • compositions useful in the present invention are compositions for enteral or parenteral use containing thiamphe col or de ⁇ vatives thereof such as, for example, thi- amphenicol glycinate and salts thereof
  • thiamphemcol glycinate acetylcysteinate is particularly preferred.
  • the amount of active ingredient, expressed as thiamphenicol, contained in the pharmaceutical composition may change depending on the administration way and on the senousness of the infection but is generally comprised between 250 mg and 5000 mg per dose, more preferably between 500 mg and 2000 mg
  • the pharmaceutical compositions can be in a solid or liquid form, suitable for administenng by lnjectable, oral or aerosol route
  • Preferred are the pharmaceutical compositions suitable for administenng by aerosol or m- jectable route
  • More preferred are the pharmaceutical compositions suitable for administenng by aerosol or m j ectable route containing thiamphemcol glycinate hydrochlonde or acetylcysteinate
  • Particularly suitable are the pharmaceutical compositions already on the market with the trademark FLUIMUCIL ANTIBIOTICO ® and GLITISOL ®
  • thiamphemcol efficacy against strams of Chlamydia pneumomae of recent clinical isolation has been demonstrated in vitro by calculating the MIC (Minimum Inhibitory Concentration) in compa ⁇ son with other antibiotics It is important to underline as thiamphemcol showed a MIC completely comparable, or better, with respect to that of reference antibiotics already used in therapy for the treatment of Chlamydia pneumomae infections
  • Chlamydia pneumomae strams Chlamydia pneumomae TW183 and Chlamydia pneumomae 2023 were obtained from American Type Culture Collection The other strains (No 9 isolated) were clinically isolated ln the penod 1997-1999 Antibiotics
  • Monolayers of Hep-2 cells were prepared by seeding 2 x 10 5 cell/ml in EMEM with 10% fetal calf serum supplemented with L-glutammine, on 12 mm cover slips and left at 35°C, 5% C0 2 for 24 to 48 hours for confluent growth The growth medium was removed and Hep-2 monolayers were inoculated with the different strains at predeterminated concentration calculated to give 3-5 x 10 2 inclusions for well
  • the monolayers, moculated with Chlamydia pneumomae were centnfuged at 1700 g for 60 minutes at 30°C Supernatant was removed and was replaced with 2 0 ml of EMEM containing 2% fetal calf serum, L-glutammine, cycloheximide 1 ⁇ g/ml and different dilutions of the tested antibiot- ICS
  • Clanthromycin and thiamphemcol glycinate acetylcysteinate are the most active anti- biotics (MIC range 0 03 and 0 25 ⁇ g/ml for both)

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PCT/EP2001/003709 2000-04-11 2001-04-02 Use of thiamphenicol for the treatment of chlamydia pneumoniae infections WO2001076585A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US09/926,738 US6833389B2 (en) 2000-04-11 2001-04-02 Use of thiamphenicol and derivatives thereof for the preparation of pharmaceutical compositions useful in the treatment of Chlamydia pneumoniae infections
DE60111811T DE60111811T2 (de) 2000-04-11 2001-04-02 Verwendung von thiamphenicol in der behandlung von infektionen verursacht durch chlamydia pneumoniae
JP2001574103A JP4796258B2 (ja) 2000-04-11 2001-04-02 クラミジア・ニューモニエ感染症の治療に有用な医薬組成物を製造するためのチアムフェニコール及びその誘導体の使用
DK01940275T DK1212049T3 (da) 2000-04-11 2001-04-02 Anvendelse af thiamphenicol til behandling af infektioner forårsaget af chlamydia pneumoniae
EP01940275A EP1212049B1 (en) 2000-04-11 2001-04-02 Use of thiamphenicol for thetreatment of chlamydia pneumoniae infections
AT01940275T ATE299020T1 (de) 2000-04-11 2001-04-02 Verwendung von thiamphenicol in der behandlung von infektionen verursacht durch chlamydia pneumoniae

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000MI000776A IT1318459B1 (it) 2000-04-11 2000-04-11 Uso del tiamfenicolo e di suoi derivati per la preparazione dicomposizioni farmaceutiche utili per il trattamento di infezioni da
ITMI2000A000776 2000-04-11

Publications (2)

Publication Number Publication Date
WO2001076585A2 true WO2001076585A2 (en) 2001-10-18
WO2001076585A3 WO2001076585A3 (en) 2002-03-28

Family

ID=11444807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003709 WO2001076585A2 (en) 2000-04-11 2001-04-02 Use of thiamphenicol for the treatment of chlamydia pneumoniae infections

Country Status (10)

Country Link
US (1) US6833389B2 (ja)
EP (1) EP1212049B1 (ja)
JP (1) JP4796258B2 (ja)
AT (1) ATE299020T1 (ja)
DE (1) DE60111811T2 (ja)
DK (1) DK1212049T3 (ja)
ES (1) ES2245367T3 (ja)
IT (1) IT1318459B1 (ja)
PT (1) PT1212049E (ja)
WO (1) WO2001076585A2 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021405A1 (it) * 2002-06-25 2003-12-29 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato respiratorio
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001378A1 (en) * 1998-06-30 2000-01-13 Karl William Baumgart Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA703436B (en) * 1969-06-07 1971-01-27 Zambon Spa A process for the preparation of thiamphenicol glycinate acetylcysteinate
DE3543021A1 (de) * 1985-12-05 1987-06-11 Boehringer Mannheim Gmbh Verbesserte verfahren zur herstellung von d-threo-1-(p-methylsulfonylphenyl) -2-dichloracetamido-propandiol-1,3-(thiamphenicol) sowie verwendung geeigneter zwischenprodukte
JPS6379822A (ja) * 1986-09-24 1988-04-09 Fujita Seiyaku Kk 動物用チアンフエニコ−ル注射用組成物及びその注射用溶液
IT1317836B1 (it) * 2000-02-16 2003-07-15 Zambon Spa Uso del tiamfenicolo per la preparazione di composizioni farmaceuticheutili per il trattamento di infezioni da staphylococci

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001378A1 (en) * 1998-06-30 2000-01-13 Karl William Baumgart Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F BLASI: "Clinical featrus of chlamydia pneumoniae acute respiratory infection" CLINICAL MICROBIOLOGY AND INFECTION, vol. 1, no. 1, 1 March 1996 (1996-03-01), pages s14-s18, XP001037674 lONDON, GREAT BRITAIN *
LOMBARDI ALESSANDRA ET AL: "Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae." ARZNEIMITTEL-FORSCHUNG, vol. 51, no. 3, 2001, pages 264-267, XP001019117 ISSN: 0004-4172 *

Also Published As

Publication number Publication date
US6833389B2 (en) 2004-12-21
DE60111811T2 (de) 2006-04-20
ES2245367T3 (es) 2006-01-01
JP4796258B2 (ja) 2011-10-19
ITMI20000776A0 (it) 2000-04-11
EP1212049B1 (en) 2005-07-06
JP2003530347A (ja) 2003-10-14
WO2001076585A3 (en) 2002-03-28
ITMI20000776A1 (it) 2001-10-11
DK1212049T3 (da) 2005-10-24
DE60111811D1 (de) 2005-08-11
IT1318459B1 (it) 2003-08-25
EP1212049A2 (en) 2002-06-12
PT1212049E (pt) 2005-11-30
ATE299020T1 (de) 2005-07-15
US20030100614A1 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
Imundo et al. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface.
Wilson et al. The biology of bacterial colonization and invasion of the respiratory mucosa
Hardy et al. Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological, and clinical overview
US20090170803A1 (en) Adjunctive treatment of biological diseases
Goldstein et al. Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae
JP5470245B2 (ja) バイオフィルム形成の処置のためのトリアゾール化合物
Rivera et al. Antibacterial effect of Morinda citrifolia fruit juice against mycoplasmas
EP1212049B1 (en) Use of thiamphenicol for thetreatment of chlamydia pneumoniae infections
Blakebrough et al. The effect of rifampicin on meningococcal carriage in family contacts in northern Nigeria
Onofrio et al. Pulmonary clearance and phagocytic cell response to normal pharyngeal flora
WO1999059566A1 (en) Use of nitric oxide synthase inhibitors in the manufacture of a medicament for the prophylaxis or treatment of bacterial infection
CN116350641A (zh) 桧木醇与磺胺异恶唑组合物及其在抑制细菌中的应用
CA2072106A1 (en) Cephalosporin compounds and method for producing them
Strateva et al. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria
US6258375B1 (en) Antibacterial phosphoinositides
EP3906251A1 (en) Thiazolyl peptides for the treatment nontuberculous mycobacterial infections
Chmel et al. A prospective, double-blind, randomized study comparing the efficacy and safety of low-dose ciprofloxacin with ampicillin in the treatment of bronchitis
WO1995028929A1 (en) Aminoline-n-oxide antimicrobials for use against h. pylori infections
Uehara et al. Metabolism: The Role of Haemophilus lnfluenzae in Lower Respiratory Infections in Childhood
US20060106117A1 (en) Compound and method for prevention and/or treatment of vaginal infections
Brumfitt et al. Pivmecillinam in complicated urinary infections failing to respond to conventional therapy
US4895870A (en) Treating chlamydia infections using spectinomycin analogs
Blandino et al. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production
JP2002534440A (ja) 感染症の治療のための３−イソキサゾリジノンおよびヒドロキシルアミン酸の使用
US20060217446A1 (en) Method for preventing and/or treating trichomonas vaginitis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 574103

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09926738

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001940275

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWP Wipo information: published in national office

Ref document number: 2001940275

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001940275

Country of ref document: EP